Expression of Costimulatory Molecules CD80 and CD86 and Their Receptors CD28, CTLA-4 on Malignant Ascites CD3+ Tumour-infiltrating Lymphocytes (TIL) from Patients with Ovarian and Other Types of Peritoneal Carcinomatosis

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1999 Dec 22

PMID 10606960

Citations 12

Authors

B Melichar

M A Nash

R Lenzi

C D Platsoucas

R S Freedman

Affiliations

Soon will be listed here.

Abstract

Costimulation of T lymphocytes by the leucocyte surface molecules CD80 and CD86 expressed on antigen-presenting cells (APC) is required for the development of T cell responses. The CD28 and CTLA-4 molecules on T cells serve as receptors for the CD80 and CD86 costimulatory antigens. We have examined the frequency of expression of CD80 (B7.1), CD86 (B7.2), CD28 and CTLA-4 surface antigens on TIL isolated from malignant ascites or peritoneal washings of 26 patients with ovarian carcinoma and five patients with non-ovarian peritoneal carcinomatosis. Expression of CD80 and CD86 antigen was detected by reverse transcription-polymerase chain reaction (RT-PCR), and by FACS analysis. Significantly higher proportions of intraperitoneal CD3+ cells expressed CD86 antigen than the CD80 antigen (14 +/- 9% versus 3 +/- 3%, P < 0.05). Moreover, CD3+CD86+ cells were significantly more frequent in the peritoneal fluid (14 +/- 9%) than in the peripheral blood (3 +/- 0.4%, P < 0.05) of ovarian patients or normal controls (3 +/- 1%). CTLA-4 and CD28 antigen were expressed, respectively, on 9 +/- 4% and 86 +/- 14% of ascitic CD3+ cells of ovarian cancer patients. Both CD80 and CD86 antigens were expressed primarily on HLA-DR+ ascites TIL and were present in a very low proportion of HLA-DR- ascites TIL. These HLA-DR+ cells may represent a population of lymphocytes that have been activated in vivo, and function as APC. An anti-CD86 MoAb or a combination of anti-CD86 and anti-CD80 MoAbs significantly inhibited the proliferation of cultured intraperitoneal TIL. We have shown that in addition to CD28 and CTLA-4, CD3+ intraperitoneal TIL express the costimulatory molecules CD80 and CD86. The expression of these molecules on T cells could be dependent upon certain factors in the tumour microenvironment that could determine the outcome of in vivo immune responses.

Citing Articles

CD200R neutrophils with dysfunctional autophagy establish systemic immunosuppression by increasing regulatory T cells.

Kim Y, Jeong Y, Bae G, Kang J, Lee M, Zabel B Cell Mol Immunol. 2024; 21(4):349-361.

PMID: 38311677 PMC: 10978921. DOI: 10.1038/s41423-024-01136-y.

Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.

Karwacki J, Kielbik A, Szlasa W, Sauer N, Kowalczyk K, Krajewski W Cells. 2022; 11(18).

PMID: 36139368 PMC: 9496996. DOI: 10.3390/cells11182793.

Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer.

Swiderska J, Kozlowski M, Gaur M, Pius-Sadowska E, Kwiatkowski S, Machalinski B Diagnostics (Basel). 2022; 12(2).

PMID: 35204342 PMC: 8871082. DOI: 10.3390/diagnostics12020251.

MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance.

Massaro C, Safadeh E, Sgueglia G, Stunnenberg H, Altucci L, DellAversana C Cells. 2021; 10(1).

PMID: 33396628 PMC: 7823834. DOI: 10.3390/cells10010039.

Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study.

Klos D, Risko J, Lovecek M, Skalicky P, Svobodova I, Krejci D World J Surg Oncol. 2019; 17(1):182.

PMID: 31694646 PMC: 6836516. DOI: 10.1186/s12957-019-1731-4.

References

Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-9. DOI: 10.1006/abio.1987.9999. View

Thurnher M, Radmayr C, Hobisch A, Bock G, Romani N, Bartsch G . Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. Int J Cancer. 1995; 62(5):559-64. DOI: 10.1002/ijc.2910620512. View

Marrack P, Kappler J . The T cell receptor. Science. 1987; 238(4830):1073-9. DOI: 10.1126/science.3317824. View

Itoh K, Platsoucas C, Balch C . Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988; 168(4):1419-41. PMC: 2189080. DOI: 10.1084/jem.168.4.1419. View

Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner E . Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem. 1989; 27:81-141. DOI: 10.1016/s0065-2423(08)60182-1. View

Wang Y, Si L, Kanbour A, Herberman R, Whiteside T . Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res. 1989; 49(21):5979-85. View

Whitford P, Mallon E, George W, Campbell A . Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer. 1990; 62(6):971-5. PMC: 1971553. DOI: 10.1038/bjc.1990.419. View

Geppert T, Davis L, Gur H, Wacholtz M, Lipsky P . Accessory cell signals involved in T-cell activation. Immunol Rev. 1990; 117:5-66. DOI: 10.1111/j.1600-065x.1990.tb00566.x. View

Ioannides C, Freedman R, Platsoucas C, Rashed S, Kim Y . Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol. 1991; 146(5):1700-7. View

10.

Ioannides C, Platsoucas C, Rashed S, Wharton J, Edwards C, Freedman R . Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 1991; 51(16):4257-65. View

11.

Linsley P, Brady W, Urnes M, Grosmaire L, Damle N, Ledbetter J . CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991; 174(3):561-9. PMC: 2118936. DOI: 10.1084/jem.174.3.561. View

12.

Xie W, Rothblum L . Rapid, small-scale RNA isolation from tissue culture cells. Biotechniques. 1991; 11(3):324, 326-7. View

13.

Young J, Koulova L, Soergel S, Clark E, Steinman R, DuPont B . The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest. 1992; 90(1):229-37. PMC: 443085. DOI: 10.1172/JCI115840. View

14.

Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71(7):1093-102. DOI: 10.1016/s0092-8674(05)80059-5. View

15.

Sansom D, Hall N . B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur J Immunol. 1993; 23(1):295-8. DOI: 10.1002/eji.1830230148. View

16.

Townsend S, Allison J . Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993; 259(5093):368-70. DOI: 10.1126/science.7678351. View

17.

Azuma M, Yssel H, Phillips J, Spits H, Lanier L . Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med. 1993; 177(3):845-50. PMC: 2190946. DOI: 10.1084/jem.177.3.845. View

18.

Linsley P, Ledbetter J . The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993; 11:191-212. DOI: 10.1146/annurev.iy.11.040193.001203. View

19.

Freedman R, Tomasovic B, Templin S, Atkinson E, Kudelka A, Edwards C . Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods. 1994; 167(1-2):145-60. DOI: 10.1016/0022-1759(94)90084-1. View

20.

Kooi S, Freedman R, RODRIGUEZ-VILLANUEVA J, Platsoucas C . Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res. 1993; 12(6):429-37. View